alexa Novel Signal Transduction Therapies For Paralysis And Pain
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Neurology & Therapeutics
September 08-10, 2014 Hilton Philadelphia Airport, USA

Chen Guang Yu
ScientificTracks Abstracts: J Neurol Neurophysiol
DOI: 10.4172/2155-9562.S1.017
Abstract
Novel effective treatments for paralysis and chronic pain are urgently needed. The objectives of the study were to: 1) target individual ERK isoforms for neuroprotection, 2) identify cross-talk between ERK1/2 and calpain 1 for joint targeting, and 3) reduce B cell signal transduction for treatments of paralysis and pain. SiRNA/shRNA approach, fenbendazole treatment, molecular, histological, and behavioral assessments were used to develop therapies targeting these signal transduction and their interactions for spinal cord injury (SCI) and pain. Lentiviral-calpain 1 shRNA treatment was shown to reduce calpain 1 signaling and pathological/functional deficits after SCI in rats. ERK2 siRNA therapy and lentiviral ERK2 shRNA therapy revealed that ERK2 signaling is a novel pathological target after SCI and pain. ERK1 activation was previously shown to attenuate excitotoxic neuronal damage and neurodegeneration. Observations in calpain1-deficient mice and pharmacological intervention following SCI showed a cross-talk between calpain 1 and ERK1/2 (calpain 1 deficiency increased activation of ERK1/2, while ERK1/2 inhibition decreased calpain 1 expression following SCI). Pain behavioral assessment demonstrated that calpain 1 deficiency exacerbated SCI-Pain after excitotoxic SCI in mice. Fenbendazole treatments were shown to reduce B cell signaling pathway and improve pathological and functional recovery after SCI in mice. Taken together, these results demonstrate that siRNA/shRNA therapies targeting individual ERK isoform and their cross-talk with calpain 1 and fenbendazole/its analogs targeting B cell signaling pathways provide greater potential as novel therapeutics for paralysis, pain, and other neurological dysfunctions.
Biography
Chen Guang Yu holds MD and PhD degrees. He completed Postdoctoral training at the University of Miami in 2000. He is currently Assistant Professor (Associate Professor, effective on April, 2014 at University of Kentucky. He has published more than 30 papers. He has also served as Associate Editor-in-Chief, Frontiers in Biology, Special Issue Editor, Journal of Spine, Scientist Reviewer on Grant Review Panels of USA Department of Defense (Pain Management 1 Award Panel and Neuroscience Grant Review Panel), and Reviewer for J Neurotrauma and other journals. His research focuses on identifying therapeutic targets and developing novel therapies for paralysis and pain.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords